SYNACT — SynAct Pharma AB Share News
0.000.00%
Last trade - 00:00- SEK821.62m
- SEK756.91m
Brief: Synact Gets Patent Term Adjustment for Resomelagon Therapy
Brief: SynAct Receives Notice Of Allowance For Grant Of U.S. Patent
Brief: Synact Pharma: USPTO Issues Patent For Syntact's Resomelagon Crystal Form
Brief: SynAct Pharma Q4 Sales SEK 0
Brief: SynAct Pharma Resolves On Directed Share Issue Of 227,203 Shares
Brief: Synact Pharma Announces Outcome Of Directed Share Issues
Brief: Synact Pharma Receives EU Trial Approval For Study With Resomelagon
Brief: Synact Pharma To Carry Out Directed Issues, Fully Guaranteed Rights Issue
Brief: SynAct Pharma Q3 Sales SEK 0
Brief: Synact Pharma Says Current Cash, Cash Equivalents Insufficient To Meet Co's Liquidity Needs Over Next 12 Months
Brief: SynAct Pharma Q2 Sales SEK 0
Brief: Anders Kronborg Is Elected As Chairman Of SynAct Pharma
Brief: SynAct Pharma Q1 Sales SEK 0
Brief: SynAct Pharma Completes Directed Issues Of 49.2 MSEK
Brief: GoodWind Distributed 977,256 Synact Pharma Shares As Dividend
Brief: Synact Pharma Appoints Jeppe Øvlesen As CEO
Brief: SynAct Pharma Updates On Resolve P2a Clinical Trial
Brief: SynAct Pharma Q4 Sales SEK 0
Brief: Synact Pharma Q4 Operating Expenses Up At SEK 91.1 Mln